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OBJECTIVES This study examined effects of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase
inhibitor cerivastatin on human saphenous vein (SV), endothelial cells (EC) and smooth
muscle cells (SMC).
BACKGROUND Venous bypass graft failure involves EC dysfunction and SMC proliferation. Substances that
improve EC function and inhibit SMC proliferation would be of clinical relevance.
METHODS Both EC and SMC were isolated from SV. Endothelial nitric oxide synthase (eNOS)
expression and nitric oxide (NO) production were analyzed by immunoblotting and
porphyrinic microsensor. The SMC proliferation was assayed by 3H-thymidine incorpora-
tion. Protein kinases and cell cycle regulators were analyzed by immunoblotting.
RESULTS Cerivastatin (1029 to 1026 mol/liter) enhanced eNOS protein expression and NO release
(about two-fold) in EC in response to Ca21 ionophore (1026 mol/liter). This was fully
abrogated by the HMG-CoA product mevanolate (2 3 1024 mol/liter). In SMC,
platelet-derived growth factor (5 ng/ml) enhanced 3H-thymidine incorporation (298 6 23%,
n 5 4), activated cyclin-dependent kinase (Cdk2), phosphorylated Rb and down-regulated
p27Kip1 (but not p21Cip1). Cerivastatin reduced the 3H-thymidine incorporation (164 6 11%,
p , 0.01), inhibited Cdk2 activation and Rb phosphorylation, but did not prevent p27Kip1
down-regulation, nor p42mapk and p70S6K activation. Mevalonate abrogated the effects of
cerivastatin on Cdk2 and Rb but only partially rescued the 3H-thymidine incorporation (from
164 6 11% to 211 6 13%, n 5 4, p , 0.01).
CONCLUSIONS In humans, SVEC inhibition of HMG-CoA/mevalonate pathway contributes to the
enhanced eNOS expression and NO release by cerivastatin, whereas in SMC, inhibition of
this pathway only partially explains cerivastatin-induced cell growth arrest. Inhibition of
mechanisms other than p42mapk and p70S6K or Cdk2 are also involved. These effects of
cerivastatin could be important in treating venous bypass graft disease. (J Am Coll Cardiol
2000;36:1691–7) © 2000 by the American College of Cardiology
Coronary bypass grafting using autologous internal mam-
mary arteries and saphenous veins (SVs) is routinely used for
treatment of patients with multivessel coronary artery dis-
ease. The patency rates of the arterial and venous grafts are,
however, quite different. Occlusions are rare in the internal
mammary artery, whereas they occur more frequently in the
vein (1,2). Occlusion of the venous grafts is the major cause
of recurrent ischemia in patients after coronary bypass
surgery. Because of a shortage of arterial graft material and
the relative ease of harvesting long vascular segments, SVs
are still widely used. Considering the large number of
patients who received venous bypass grafts in the last
decades, the increasing incidence of venous bypass graft
disease made the development of approaches to treat such
patients an important therapeutic challenge.
Venous bypass graft failure is primarily related to biolog-
ical properties of endothelial cells (ECs) and smooth muscle
cells (SMCs) (3,4). The endothelium of the SV releases
much less nitric oxide (NO) compared with that of the
internal mammary artery (3,4). Nitric oxide is produced
from L-arginine via endothelial nitric oxide synthase
(eNOS) and is a potent vasodilator, platelet inhibitor and
anti-proliferative agent (5). In the arterial circulation, the
venous endothelium is unable to prevent platelet-vessel wall
interaction, which favors thrombus formation and vascular
occlusion (6). Furthermore, SMCs from SVs grow exces-
sively in response to several growth factors such as platelet-
derived growth factor (PDGF) and thrombin (4,7,8). This
may contribute to the lower long-term patency rate of
venous grafts.
Although mechanisms of cell growth regulation have not
yet been fully understood, recent evidence suggests that
signal transduction molecules such as MAPK, PI-3K and
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p70S6K, which are activated by tyrosine kinase receptors
such as PDGF receptors, are important for cell cycle
progression (9–11). Cell cycle progression is positively
regulated by the orderly activation of cyclin-dependent
kinases (Cdks) and negatively regulated by several Cdk
inhibitors known as CKIs (12–14). p27Kip1 is most likely
involved in cell cycle control in human SV SMC (8). Cyclin
D-Cdk4/Cdk6 regulates G1 progression, and cyclin
E-Cdk2 is essential for G1/S transition by phosphorylating
and inactivating the tumor suppressor gene product, pRB
(12–14), which causes release and activation of E2F tran-
scription factor and in turn regulates several proteins re-
quired for cell proliferation (14).
Lipid-lowering therapy with 3-hydroxy-3-methylglutaryl
CoA (HMG-CoA) reductase inhibitors strikingly decreases
cardiovascular morbidity and mortality (15–18). The effects
of those agents have been attributed to inhibition of
cholesterol synthesis and lowering of low-density lipopro-
tein plasma levels. However, not all the clinical benefits of
the agents can be explained by their lipid-lowering effects
(19). Moreover, whether all the effects of statins could be
explained by inhibition of HMG-CoA reductase is not
clear. A recent study indicates that HMG-CoA reductase
inhibitors could possess biological effects independent of
HMG-CoA reductase (20).
In the clinical setting no optimal therapy for venous
bypass graft disease is available (21). This may be related, at
least in part, to the fact that antiproliferative drugs may not
be able to improve endothelial function and at the same
time inhibit SMC proliferation. In this study, we hypoth-
esized that the new HMG-CoA reductase inhibitor ceriv-
astatin could meet these criteria in human SVs and therefore
may have the important clinical impact of improving venous
bypass graft function. Moreover, we also investigated
whether cerivastatin affects EC and SMC function in
human SVs solely by the classic mechanism (i.e., inhibition
of HMG-CoA reductase).
METHODS
Chemicals and materials. Bovine serum albumin (BSA,
7.5%), monoclonal antibody against smooth muscle a-actin,
and all chemicals for immunoblotting were from Sigma
(Buchs, Switzerland); recombinant human PDGF-BB was
from (R&D Systems GmbH, Wiesbaden, Germany); all
tissue culture materials were from Gibco (Basel, Switzer-
land); 3H-methyl-thymidine was from Amersham (Zu¨rich,
Switzerland); trichloroacetic acid was from Fluka (Buchs,
Switzerland); rabbit polyclonal anti-human p42mapk (C14),
p27Kip1 (C19), and Cdk2 (M2) were from Santa Cruz
Biotechnol (Basel, Switzerland); mouse monoclonal anti-
body against human p21Cip1 (Clone EA10) was from
Calbiochem (JURO Supply AG, Lucerne, Switzerland);
mouse monoclonal antibody against human eNOS
(N30020) was from Transduction Laboratories (Basel,
Switzerland); rabbit polyclonal anti-human phospho-pRB
(Ser807/811) was from New England BioLabs (Schwalbach/
Taunus, Germany); mevalonate was from Sigma (Buchs,
Switzerland); and cerivastatin was kindly supplied by Bayer
AG (Leverkusen, Germany).
Cultivation of ECs and SMCs. Endothelial cells were
isolated from human SVs as described (4). Briefly, fresh
blood vessels were harvested in a cold sterile RPMI-1640
medium with antibiotics (100 U/ml penicillin and
100 mg/ml streptomycin). The vessels cleaned of connective
tissue and adventitia were incubated with collagenase
type II 75 U/ml for 15 min in phosphate-buffered saline
(PBS). Cell pellets were then collected by centrifugation at
1,000 rpm for 10 min and seeded in culture dishes coated
with 25 mg/ml human fibronectin and cultured in RPMI-
1640 supplemented with 20 mmol/liter L-glutamine,
HEPES buffer solution, 100 U/ml penicillin and 100 mg/ml
streptomycin, 50 mg/ml endothelial cell growth supplement,
25 mg/ml heparin and 20% fetal calf serum (FCS). The day
after, cells were washed with the medium to eliminate blood
cell contamination. Endothelial cells were characterized by
typical cobblestone and nonoverlapping appearance and
indirect immunofluorescence staining using specific anti-
bodies against von Willebrand factor. Cells of third and
fourth passage were used.
Vascular SMC were cultivated from SVs obtained from
patients undergoing coronary bypass surgery using explant
technique as previously described (4,8). Briefly, the cells
were cultured in Dulbecco’s modified eagle medium con-
taining 20% FCS supplemented with 20 mmol/liter
L-glutamine and HEPES buffer solution, 100 U/ml peni-
cillin and 100 mg/ml streptomycin in a humidified atmo-
sphere (37°C; 95% air/5% CO2). Culture medium was
replaced every three days. Cells were passaged by trypsina-
tion (0.01% EDTA). Experiments were performed between
passages five to eight. The SMC were characterized by
typical morphological pattern (multilayer sheets and “hills
and valleys”) and indirect immunofluorescence staining
using specific mouse monoclonal antibodies against human
SMC a-actin (Sigma).
The eNOS expression. Confluent ECs were rendered
quiescent for 24 h by changing the medium to RPMI-1640
with the same ingredients as described above except that EC
growth supplement and heparin were avoided and only 0.5%
FCS was added. The cells were then treated with cerivas-
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tatin at different concentrations in the presence or absence
of mevalonate for 24 h and then washed twice with PBS and
harvested in the extraction buffer (120 mmol/liter sodium
chloride, 50 mmol/liter Tris, 20 mmol/liter sodium fluoride,
1 mmol/liter benzamidine, 1 mmol/liter DTT, 1 mmol/liter
EDTA, 6 mmol/liter EGTA, 15 mmol/liter sodium pyro-
phosphate, 0.8 mg/ml leupeptin, 30 mmol/liter p-nitrophenyl
phosphate, 0.1 mmol/liter PMSF, and 1% NP-40) for
immunoblotting. All cell debris were removed by centrifu-
gation at 12,000 g for 10 min at 4°C. The samples (20 mg)
were treated with 5xLaemmli’s SDS-PAGE sample buffer
(0.35 mol/liter Tris-Cl, pH 6.8, 15% SDS, 56.5% glycerol,
0.0075% bromophenol blue), followed by heating at 95°C
for 3 min and then subjected to 8% SDS-PAGE gel for
electrophoresis. The proteins were then transferred onto
ImmobilonTM-P filter papers (Millipore AG, Volketswil,
Switzerland) with a semi-dry transfer unit (Hoefer Scien-
tific, Switzerland). The membranes were then blocked by
using 5% skim milk in PBS-Tween buffer (0.1% Tween 20;
pH 5 7.5) for 1 h and incubated with the antibody against
human eNOS (1:600). The immunoreactive bands were
detected by an enhanced chemiluminescence system (Amer-
sham, Zu¨rich, Switzerland).
Measurement of NO release. In parallel experiments the
cells treated with cerivastatin and mevalonate as described
above were used for measurement of NO release by por-
phyrin microsensor (22). Amperometric mode detection
was used at a constant potential equal to the peak potential
for NO oxidation of the electrode. The NO concentration
was determined from the measured current by means of a
calibration curve with NO standards. Standard NO solu-
tions (1.8 mmol/liter) were prepared from aequeous solu-
tions saturated with pure gaseous NO. Immediately before
NO measurements, the active tip of the L-shaped porphy-
rinic NO microsensor was placed directly on the surface of
the EC monolayer. The monolayer had been washed three
times with PBS, pre-warmed to 37°C, immediately before
the measurements. For maximal stimulation of eNOS,
Ca21 ionophore A23187 was injected into the cell culture
dish to yield a final concentration of 1026 mmol/liter. In
some experiments, EC monolayers were pre–incubated with
L-NAME (1024 mmol/liter) for 15 min before NO mea-
surements. Only a very marginal signal could be recorded
under this condition, and this was subtracted during the
calculation.
3H-Thymidine. The SV SMCs were seeded on 12-well
plates at a density of 2 3 104/well and exposed to
PDGF-BB in the presence or absence of cerivastatin or
cerivastatin plus mevalonate. The DNA synthesis was mea-
sured by 3H-thymidine (1 mCi/ml; 70 to 85 Ci/mol)
incorporation after 24 h as described (4,8).
Activation of protein kinase. Activation of MAPK as well
as p70S6K were analyzed by mobility shift of the kinases on
Western blots as described (4,8). The cells were pre–treated
with different substances tested, then stimulated with
PDGF-BB (10 ng/ml) for 10 min and harvested in the
extraction buffer as previously described (8). Cell lysates
above 20 mg were treated with 5xLaemmli’s SDS-PAGE
sample buffer and subjected to 10% SDS-PAGE gel for
electrophoresis. Western blot was performed by using spe-
cific antibodies.
Cell cycle regulatory proteins. The cells were stimulated
with PDGF-BB (10 ng/ml) in the presence or absence of
cerivastatin or cerivastatin plus mevalonate for 24 h, and
then harvested with extraction buffer as described (8).
Regulation of CKIs (p21Cip1 and p27Kip1), Cdk2 and pRb
phosphorylation by PDGF-BB was analyzed by immuno-
blotting as described above; 12% SDS-PAGE was used for
analysis of p21Cip1 and p27kip1; Cdk2 and 8% SDS-PAGE
were used for detection of phosphorylation of pRb.
Statistics. Data are means 6 SEM. The 3H-thymidine
incorporation and MAPK activity were expressed as percent
increase above control. In all experiments, n equals the
number of patients from which vessels were obtained. The
Student t test for paired observations and analysis of
variance followed by the Scheffe test for repeated measure-
ments were used. A two-tailed p value smaller than 0.05 was
considered significant.
RESULTS
Effects of cerivastatin on eNOS. In cultured human
SV-EC, treatment of the cells with cerivastatin (1029 to
1026 mol/liter; 24 h) up-regulated the eNOS protein level
in a concentration-dependent manner (Fig. 1, top panel).
Densitometry showed that the increase in eNOS protein
level reached about two-fold (Fig. 1, lower panel, n 5 3).
This up-regulation of eNOS expression by cerivastatin
(1026 mol/liter) was fully reversed by mevalonate (2 3 104
mol/liter) (Fig. 2A, B). Accordingly, NO production stim-
ulated by Ca21 ionophore (1026 mol/liter) in the cells
treated with cerivastatin (1026 mol/liter) for 24 h was also
markedly increased (from 393 6 55 nmol/liter to 840 6
Figure 1. Effects of cerivastatin on eNOS expression in human saphenous
vein endothelial cells: Immunoblotting demonstrated up-regulation of
eNOS by the HMG-CoA reductase inhibitor cerivastatin (Ceri) in a
concentration-dependent manner. Densitometry showed about two-fold
increase in eNOS protein level (n 5 3).
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42% nmol/liter, n 5 3, p , 0.01) as measured by the
porphyrinic microsensor (Fig. 2C). Similar to eNOS pro-
tein expression, the enhanced NO release by cerivastatin
was also fully reversed by treatment of the cells with
mevalonate (2 3 104 mol/liter; Fig. 2C, 372 6 78 nmol/
liter, p , 0.01 vs. cerivastatin-treated cells), whereas meva-
lonate alone had no effects.
Effects of cerivastatin on SMC proliferation. In cultured
human SV SMC, the growth factor PDGF-BB (5 ng/ml)
markedly enhanced 3H-thymidine incorporation (298 6
23% above control, n 5 4), which was concentration-
dependently inhibited by cerivastatin (data not shown). The
inhibitory effects of cerivastatin (1026 mol/liter; 164 6
11%) was only partially abrogated by co-incubation of the
cells with mevalonate (2 3 104 mol/liter; 211 6 13%, Fig.
3; n 5 4, p , 0.05 vs. cerivastatin plus PDGF). Mevalonate
alone had no effects on 3H-thymidine incorporation.
Effects of cerivastatin on MAPK and p70S6K activation.
After stimulation of SMC with PDGF-BB (10 ng/ml,
10 min) both p42mapk and p70S6K were activated, as
demonstrated by a slower mobility of the activated (phos-
phorylated) kinase on Western blots (Fig. 4). Cerivastatin
(1026 mol/liter) did not exhibit inhibitory effects on either
p42mapk or p70S6K activation in response to PDGF-BB
(Fig. 4). By contrast, activation of p42mapk was specifically
inhibited by PD98059 (5 3 1025 mol/liter), a specific
MAPK kinase (MEK) inhibitor. The p70S6K activation
stimulated by PDGF-BB (10 ng/ml) was prevented by
rapamycin (1025 mol/liter), a specific inhibitor of p70S6K,
and also by wortmannin (1025 mol/liter), a specific inhibitor
of PI3-K (Fig. 4).
Effects of cerivastatin on cell cycle regulators. Western
blotting demonstrated that stimulation of the SV SMC
with PDGF-BB (10 ng/ml) for 24 h induced activation of
Cdk2 accompanied by an increase in its electrophoretic
Figure 2. Cerivastatin up-regulates eNOS protein level and enhances NO
release via inhibition HMG-CoA reductase: (A) Immunoblotting demon-
strated that in cultured human saphenous vein endothelial cells, cerivastatin
(1026 mol/liter, 24 h) enhanced eNOS protein level, which was fully
reversed by the HMG-CoA product mevalonate (Meva, 2 3 1024
mol/liter). (B) Quantification of the experiments above by densitometry
(n 5 3). (C) In cells treated with cerivastatin (1026 mol/liter, 24 h), NO
release stimulated by Ca21 ionophore (1026 mol/liter) as measured by
porphyrinic microsensor was significantly enhanced. This enhancement of
NO release was fully reversed by mevalonate (2 3 1024 mol/liter; n 5 3).
* 5 p , 0.01 vs. control; † 5 p , 0.01 vs. cerivastatin plus mevalonate.
Figure 3. Cerivastatin inhibits human saphenous vein smooth muscle cell
growth: PDGF-BB (5 ng/ml, 24 h) enhanced 3H-thymidine incorpora-
tion, which was markedly reduced by cerivastatin (1026 mol/liter; n 5 4).
The inhibitory effect of cerivastatin on 3H-thymidine incorporation was
only partially reversed by co-incubation of the cells with the HMG-CoA
product mevalonate (2 3 1024 mol/liter). * 5 p , 0.01 vs. control; † 5
p , 0.01 vs. PDGF; ‡ 5 p , 0.01 vs. PDGF plus cerivastatin.
Figure 4. Effects of cerivastatin on p42mapk and p70S6K: In cultured human
saphenous vein, SMC PDGF-BB (10 ng/ml, 10 min) markedly stimulated
(or phosphorylated) p42mapk as demonstrated by the slower mobility of the
enzyme on Western blots. The activation of p42mapk was not inhibited by
cerivastatin (1026 mol/liter), but was markedly reduced by the specific
inhibitor of MAPK kinase (MEK), PD98059 (5 3 1025 mol/liter), while
the PI3K inhibitor (wortmannin, 1025 mol/liter) or the p70S6K inhibitor
(rapamycin, 1025 mol/liter) had no effects on p42mapk activation. The same
blots were used for analysis of p70S6K. PDGF-BB stimulated p70S6K
activation (or phosphorylation) as demonstrated by the slower mobility of
the enzyme on Western blots, which was not influenced by cerivastatin or
by PD98095, the specific inhibitor of MEK. In contrast, activation of
p70S6K was completely prevented by wortmannin or rapamycin. The results
were repeated with three independent experiments.
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mobility on SDS-PAGE (Fig. 5) due to Cdk2 phosphory-
lation on Thr160 (23), down-regulation of p27Kip1 and
phosphorylation of pRb. In contrast, p21Cip1 was not
down-regulated by PDGF-BB (Fig. 5). Cerivastatin (1026
mol/liter) inhibited PDGF–induced activation of Cdk2 and
pRb phosphorylation but had no significant effects on the
down-regulation of p27Kip1 (Fig. 5). These effects of ceriv-
astatin on Cdk2 and Rb were almost fully reversed by
mevalonate (2 3 1024 mol/liter).
DISCUSSION
The present finding. The major findings of the present
study are that in human SV the HMG-CoA reductase
inhibitor cerivastatin enhances eNOS protein level and NO
release by the classic mechanism (i.e., inhibition of HMG-
CoA reductase) in EC, whereas inhibition of HMG-CoA
reductase only partially contributes to the inhibitory effects
of cerivastatin on SMC growth in response to PDGF.
Mechanisms other than inhibition of p42mapk, PI-3K/
p70S6K or Cdk2 are involved.
Effect of cerivastatin on SV EC. Clinical trials demon-
strated that HMG-CoA reductase inhibitors markedly re-
duce mortality and morbidity in patients with coronary
artery disease or stroke (15–17,24). There is increasing
evidence that HMG-CoA reductase inhibitors exhibit sev-
eral beneficial effects via non-lipid-dependent mechanisms
(19). In line with the experiments with simvastatin and
lovastatin (18,25–27), the present study demonstrated that
cerivastatin enhanced eNOS protein expression and NO
release by Ca21 ionophore in the same cells. These effects of
cerivastatin were fully abrogated by the HMG-CoA prod-
uct mevalonate, indicating that cerivastatin up-regulates
eNOS protein level via inhibition of HMG-CoA reductase
in the human SV EC. By contrast, inhibition of HMG-
CoA reductase in bovine aortic ECs does not increase
eNOS expression (28). The mechanism for the discrepancy
is not clear. It might be due to the different cell types used.
The molecular mechanism of increase in eNOS expression
by statins in the human SV EC is due to inhibition of Rho
GTPase, whose activation is dependent on prenylation
induced by mevalonate metabolites and negatively regulates
stability of eNOS mRNA. (26,27). Our results provide
evidence that the HMG-CoA reductase inhibitors help to
adapt endothelial function in the human SV to the arterial
circulation where higher amounts of NO production are
required than the venous side.
Effect of cerivastatin on SV SMCs. In addition to endo-
thelial dysfunction, an enhanced vascular SMC growth also
importantly contributes to human venous bypass graft fail-
ure (6–8). Our previous study demonstrated that the
growth factor PDGF released from aggregating platelets at
the site of vascular injury is an important mediator of SV
SMC growth (8). Further evidence demonstrated that
p42/44mapk, PI-3K and p70S6K are important signaling
molecules for cell growth (9–11). The present study dem-
onstrated that cerivastatin is a potent inhibitor of SMC
growth of the SV. However, the inhibitory effect of ceriv-
astatin on the SMC growth is only partially reversed by the
HMG-CoA product mevalonate, indicating that, unlike in
the ECs, inhibition of the HMG-CoA/mevalonate path-
way only partially contributes to the inhibitory effect of the
drug on SMC growth. Other studies showed that HMG-
CoA reductase inhibitors prevent cell growth by blocking
Rho GTPase via inhibition of the protein prenylation
induced by mevalonate metabolites (29–31). The results
from the present study with mevalonate suggest that this
mechanism is only partially involved in cell growth. We
further analyzed whether cerivastatin could interfere with
other signal transduction mechanisms such as p42mapk and
p70S6K. Interestingly, our results showed that cerivastatin
did not influence p42mapk or p70S6K activation. This sug-
gests that cerivastatin inhibits SMC growth via mechanisms
other than p42mapk and p70S6K. The exact mechanisms
remain to be explored.
The cell growth is positively regulated by the orderly
activation of Cdks and negatively regulated by several Cdk
inhibitors (12–14). In the present study we demonstrated
that the growth factor PDGF activated Cdk2 and phos-
phorylated Rb, both of which were inhibited by cerivastatin.
These effects of cerivastatin were almost fully reversed by
mevalonate, indicating that cerivastatin prevented PDGF-
induced Cdk2 activation and Rb phosphorylation via the
classic mechanism (i.e., inhibition of HMG CoA reduc-
tase). Of note, the rescuing effects of mevalonate on Cdk2
and Rb were not fully correlated with the reversal of
3H-thymidine incorporation by the substance. Only about
one-third of the inhibition of 3H-thymidine incorporation
by cerivastatin was reversed by mevalonate. This indicates
that inhibition of HMG-CoA reductase linked to Cdk2
blockade is only one mechanism of the drug-induced
growth arrest of SMCs. It is possible that other cell-cycle
regulatory proteins are still inhibited by cerivastatin inde-
pendent on HMG-CoA/mevalonate pathway. This issue
needs additional investigation.
Furthermore, results of the present study showed that
p27Kip1, but not p21Cip1, was down-regulated by PDGF.
Figure 5. Effects of cerivastatin on cell-cycle regulatory proteins: Western
blotting demonstrated that stimulation of human vascular smooth muscle
cells with PDGF-BB (10 ng/ml) for 24 h induced activation of Cdk2,
phosphorylation of pRb and down-regulation of p27Kip1, but not p21Cip1.
Cerivastatin (1026 mol/liter) inhibited Cdk2 activation and pRb phosphor-
ylation, but did not prevent the down-regulation of p27Kip1. The p21Cip1
was also not influenced by cerivastatin. The effects of cerivastatin on Cdk2
and Rb were reversed by the HMG-CoA product mevalonate (2 3 1024
mol/liter). The results were repeated with three independent experiments.
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This confirmed our previous study (8) showing that p27Kip1
is most likely involved in cell growth regulation of these
cells. Several studies showed that inhibition of HMG-CoA
reductase prevents p27Kip1 or p21Cip1 down-regulation in
established cell lines (32,33). To our surprise, the present
study demonstrated that cerivastatin was unable to prevent
the down-regulation of p27Kip1, indicating that HMG-
CoA/mevalonate pathway is not involved in the regulation
of the cell-cycle inhibitor in these particular human cells.
In IIC9 cells, a subculture of Chinese hamster embryo
fibroblasts and also in FRTL-5 cells, a strain of rat thyroid
cells, p27Kip1 down-regulation or degradation is dependent
on Cdk2 activation through RhoA (29,34). However, this
mechanism seems not to contribute to the down-regulation
of the Cdk inhibitor in our cells, because inhibition of Cdk2
activation by cerivastatin did not correlate with up-
regulation of p27Kip1. Our data contrast with the observa-
tion by Laufs et al. (35), who did show prevention of
p27Kip1 down-regulation by another statin simvastatin in
cultured SMCs from human aorta and SV. Unfortunately,
this study did not specify the cell types from which the
results were raised. It is also possible that simvastatin may
have different effects on p27Kip1 than cerivastatin. This issue
will be further investigated.
Conclusions. A recent clinical post-CABG trial showed
that the progression of atherosclerosis in SV grafts was
delayed by aggressive lovastatin treatment but not by mod-
erate treatment (36). Because NO release in the human SV
is very low, and excessive SMC proliferation importantly
contributes to the poor long-term patency rate of venous
grafts, the effects of cerivastatin on human SV EC and
SMCs as shown in this study may be beneficial for patients
with venous bypass grafts.
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